COMP-13. EARLY TUMOR VOLUME EVOLUTION ADAPTIVELY PREDICTS PATIENT-SPECIFIC RESPONSE AND PROGRESSION RISK TO RADIOTHERAPY, PEMBROLIZUMAB, AND BEVACIZUMAB IN RECURRENT HIGH-GRADE GLIOMA IN A PHASE I TRIAL

PURPOSE/OBJECTIVES: We set out to predict response and progression risk in recurrent high-grade glioma patients treated with hypofractionated stereotactic radiation plus pembrolizumab and bevacizumab (NCT02313272). At present RANO criteria define progression as 25% increase in sum of the products of...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Neuro Oncol
Hoofdauteurs: Glazar, Daniel, Brady, Rene, Howard, Rachel, Grass, Daniel, Arrington, John, Yu, Michael, Raghunand, Natarajan, Sahebjam, Solmaz, Enderling, Heiko
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Oxford University Press 2019
Onderwerpen:
Computational Omics
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6847129/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz175.256
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items